Patents by Inventor Marco Muda

Marco Muda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION USING ANTI-ANG2 X VEGF MULTI-SPECIFIC ANTIBODIES
    Publication number: 20240158489
    Abstract: The present disclosure relates generally to methods for treating choroidal neovascularization in a subject in need thereof using anti-ANG-2×VEGF multi-specific antibodies.
    Type: Application
    Filed: March 29, 2022
    Publication date: May 16, 2024
    Inventors: Marco Muda, James Lulo
  • ANTI-CLAUDIN 18.2 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20230279152
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g multi-specific antibodies or antigen binding fragments thereof) that can bind to the Claudin 18.2 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a Claudin 18.2-associated cancer in a subject in need thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Inventors: Gang AN, Zusheng LI, Yuan LIU, Adam PELZEK, Shaun MURPHY, Lucy ZHANG, Shengqin WAN, Yangde CHEN, Marco MUDA, James LULO, Wei LI
  • ANTI-TNFR2 ANTIBODIES AND USES THEREOF
    Publication number: 20220281990
    Abstract: Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 8, 2022
    Inventors: Yu ZHOU, James D. MARKS, Marco MUDA, James Frank SAMPSON, Eric M. TAM, Ross Bane FULTON
  • ANTI-TNFR2 ANTIBODIES AND USES THEREOF
    Publication number: 20210371537
    Abstract: Anti-TNFR2 antibodies which bind to particular human TNFR2 epitopes, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer are disclosed.
    Type: Application
    Filed: September 18, 2019
    Publication date: December 2, 2021
    Inventors: Eric M. TAM, Marco MUDA, Klaus Andreas RAUE, Vinodh B. KURELLA, Daryl Clark DRUMMOND, Ross Bane FULTON, Fabien DEPIS, Anne-Sophie DUGAST, Jian TANG, Sandeep KUMAR
  • ANTI-FGFR ANTIBODIES AND METHODS OF USE
    Publication number: 20180244785
    Abstract: Anti-FGFR antibodies which bind to particular isoforms of FGFR1-4, therapeutic compositions comprising the anti-FGFR antibodies, and methods of using such antibodies and compositions in the treatment of FGFR-related disorders (e.g., cancer) are disclosed.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 30, 2018
    Inventors: Tamara DAKE, Gregory J. FINN, Melissa GEDDIE, Yasmin HASHAMBHOY-RAMSAY, Marco MUDA, Birgit M. SCHOEBERL
  • FSH glycosylation variant D3N
    Patent number: 7956034
    Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: June 7, 2011
    Assignee: Merck Serono SA
    Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
  • FSH mutants
    Patent number: 7740862
    Abstract: FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: June 22, 2010
    Assignee: Merck Serono S.A.
    Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
  • Fsh Mutants
    Publication number: 20090018070
    Abstract: FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.
    Type: Application
    Filed: December 21, 2006
    Publication date: January 15, 2009
    Applicant: LABORATOIRES SERONO SA
    Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
  • Novel Fsh Glycosylation Variant D3n
    Publication number: 20080280832
    Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
    Type: Application
    Filed: January 16, 2007
    Publication date: November 13, 2008
    Applicant: Laboratoires Serono SA
    Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
  • Spliced variants of lgr6
    Publication number: 20060205924
    Abstract: The present invention provides Leucine-Rich Repeat-Containing G-Protein Coupled Receptor-6 (LGR6-Vs) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing LGR6-SVs polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with LGR6-SVs polypeptides.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 14, 2006
    Inventor: Marco Muda